These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33867900)

  • 21. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern.
    Cao L; Guo J; Li H; Ren H; Xiao K; Zhang Y; Zhu S; Song Y; Zhao W; Wu D; Chen Z; Zhang Y; Xia B; Ji T; Yan D; Wang D; Yang Q; Zhou Y; Li X; Hou Z; Xu W
    Microbiol Spectr; 2023 Feb; 11(2):e0268722. PubMed ID: 36847495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity.
    Mengist HM; Kombe Kombe AJ; Mekonnen D; Abebaw A; Getachew M; Jin T
    Semin Immunol; 2021 Jun; 55():101533. PubMed ID: 34836774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.
    Wambani J; Okoth P
    Egypt J Intern Med; 2022; 34(1):34. PubMed ID: 35368846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
    Noor R; Shareen S; Billah M
    Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.
    Padhiar NH; Liu JB; Wang X; Wang XL; Bodnar BH; Khan S; Wang P; Khan AI; Luo JJ; Hu WH; Ho WZ
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 variants - Evolution, spike protein, and vaccines.
    Chen KK; Tsung-Ning Huang D; Huang LM
    Biomed J; 2022 Aug; 45(4):573-579. PubMed ID: 35526825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.
    Rudi E; Martin Aispuro P; Zurita E; Gonzalez Lopez Ledesma MM; Bottero D; Malito J; Gabrielli M; Gaillard E; Stuible M; Durocher Y; Gamarnik AV; Wigdorovitz A; Hozbor D
    Front Immunol; 2022; 13():1020159. PubMed ID: 36248791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VSV-ΔG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants.
    Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Achdout H; Erez N; Israeli O; Cohen-Gihon I; Chery Mimran L; Barlev-Gross M; Mandelboim M; Orr I; Feldmesser E; Weiss S; Beth-Din A; Paran N; Israely T
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
    Martínez-Flores D; Zepeda-Cervantes J; Cruz-Reséndiz A; Aguirre-Sampieri S; Sampieri A; Vaca L
    Front Immunol; 2021; 12():701501. PubMed ID: 34322129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamical changes of SARS-CoV-2 spike variants in the highly immunogenic regions impact the viral antibodies escaping.
    Di Rienzo L; Miotto M; Desantis F; Grassmann G; Ruocco G; Milanetti E
    Proteins; 2023 Aug; 91(8):1116-1129. PubMed ID: 37078559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
    Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
    Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.
    Woldemeskel BA; Garliss CC; Blankson JN
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine.
    Sayedahmed EE; Araújo MV; Silva-Pereira TT; Chothe SK; Elkashif A; Alhashimi M; Wang WC; Santos AP; Nair MS; Gontu A; Nissly R; Francisco de Souza Filho A; Tavares MS; Ayupe MC; Salgado CL; Donizetti de Oliveira Candido É; Leal Oliveira DB; Durigon EL; Heinemann MB; Morais da Fonseca D; Jagannath C; Sá Guimarães AM; Kuchipudi SV; Mittal SK
    Mol Ther Methods Clin Dev; 2023 Sep; 30():194-207. PubMed ID: 37502665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.
    Singh DD; Parveen A; Yadav DK
    Front Cell Infect Microbiol; 2021; 11():777212. PubMed ID: 34970509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021.
    Alkhatib M; Svicher V; Salpini R; Ambrosio FA; Bellocchi MC; Carioti L; Piermatteo L; Scutari R; Costa G; Artese A; Alcaro S; Shafer R; Ceccherini-Silberstein F
    Microbiol Spectr; 2021 Dec; 9(3):e0109621. PubMed ID: 34787497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines.
    Hoffmann MAG; Yang Z; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Nakatomi LM; Storm KN; Moon WJ; Lin PJC; West AP; Bjorkman PJ
    Cell; 2023 May; 186(11):2380-2391.e9. PubMed ID: 37146611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.